PofoliaShared via Pofolia

Alzheimer s & Dementia· 2026Q1

A murine model of amyloid‐enhanced tauopathy: Comparison of wild‐type and P301L‐tau

Dylan J. Finneran, Taylor Desjarlais, Brianna M. Jackman, Marcia N. Gordon et al.

Short summary

In mice with mature amyloid, wild-type (WT) tau was more hyperphosphorylated and caused cognitive impairment, despite P301L-tau showing greater phospho-tau deposition and neurofibrillary tangle formation.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Mice with mature amyloid injected with WT or P301L tau showed similar spatial learning and memory impairments.
  • WT tau was significantly more hyperphosphorylated than P301L tau in the presence of amyloid.
  • P301L tau exhibited greater deposition of phospho-tau and formation of neurofibrillary tangles.
  • WT tau induced cognitive impairment even without neurofibrillary tangle pathology.

AI-generated from the title and abstract; the full text is not read.

Abstract

INTRODUCTION: To optimize a model of amyloid-enhanced tauopathy we compared wild-type (WT) tau with P301L-tau in a mouse with mature amyloid. METHODS: Mice transgenic for amyloid precursor protein and presenilin-1 (APP+PS1, A/P) were injected intravenously with adeno-associated virus with capsid B10 (AAV.CAP-B10) expressing either WT or P301L human tau. Mice were behaviorally assessed 5 and 8 months and tissue collected 9 months after injection. RESULTS: A/P+WT and A/P+P301L groups were equivalently impaired in spatial learning and memory. A/P+WT mice had significantly greater tau hyperphosphorylation than A/P+P301L mice. However, A/P+P301L mice had greater deposition of phospho-tau and formation of Gallyas-positive neurofibrillary tangles (NFTs). DISCUSSION: These data demonstrate that WT-tau is more highly phosphorylated than P301L-tau in the presence of amyloid in mouse brain. Furthermore, despite the lack of NFT pathology in A/P+WT mice, WT-tau still caused cognitive impairment. The use of WT-tau in this model may make it more translatable for pre-clinical assessments of potential therapeutics for AD.

The authors' abstract, as published at the source. Alzheimer s & Dementia, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Physiology

PhysiologyMedicine